Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiujiujiu is a Chinese industrial company focused on specialty chemicals, pharmaceutical intermediates, and selected new materials rather than an innovative drug-development biotech pipeline. Publicly available descriptions link the business to large-scale production of pharmaceutical intermediates such as 7-amino-desacetoxy cephalosporanic acid, as well as other chemicals including benzaldehyde, 5,5-dimethylhydantoin, lithium hexafluorophosphate, and ultra-high molecular weight polyethylene fiber. The company appears to operate as a manufacturing-oriented enterprise serving downstream pharmaceutical, chemical, and materials markets. It has historically been associated with the listed company ticker 002411 and later with the Yan'an Bikang group, and third-party sources indicate it was acquired by Jiangsu Bicon Pharmaceutical Listed in September 2024. Overall, this is best characterized as a commercial-stage chemical and pharma-intermediate manufacturer with some healthcare relevance, not a therapeutic drug discovery company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiujiujiu.